PARAGON- LCZ696 vs valsartan in patients with chronic heart failure

• Research type

  Research Study

• Full title

  A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.

• IRAS ID

  137191

• Contact name

  Theresa McDonagh

• Contact email

  theresa.mcdonagh@kcl.ac.uk

• Sponsor organisation

  Novartis Pharma services AG

• Eudract number

  2013-001747-31

• ISRCTN Number

  Not known

• Clinicaltrials.gov Identifier

  Not known

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/1328

• Date of REC Opinion

  24 Oct 2013

• REC opinion

  Further Information Favourable Opinion